Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 26;64(2):3098.
doi: 10.4081/ejh.2020.3098.

Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence

Stanislav Ziaran  1 , Stefan Harsanyi, Katarina Bevizova, Zuzana Varchulova Novakova, Branislav Trebaticky, Peter Bujdak, Stefan Galbavy, Lubos Danisovic
Affiliations

Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence

Stanislav Ziaran et al. Eur J Histochem. .

Abstract

Although the incidence varies with age and gender, urothelial bladder cancer is a relatively frequently occurring malignancy with variable clinical behavior that often has high recurrence rates. In this study, we analyzed the tumor tissues of 224 patients with pTa, pT1, and pT2 urinary bladder cancer. We performed a histomorphologic analysis and immunohistochemistry for p53, Ki-67, and E-cadherin, which were selected as markers of the malignant process. For pTa and pT1, univariate analyses of cancer-specific survival (CSS), progression-free survival (PFS), and recurrence-free survival (RFS) were calculated using the Kaplan-Meier method, the log-rank test and Cox regression. Multivariate analysis was performed by a Cox regression analysis. Ki-67 (P<0.001) was significantly associated with CSS, but the highest association was shown for E-cadherin (P<0.001). For pT1 and pTa, the Kaplan-Meier analysis and the log-rank test revealed significantly worse PFS for patients with higher levels of Ki-67 (P<0.001) and lower levels of E-cadherin (P<0.001). Based on these obtained results, it can be clearly stated that Ki-67 and E-cadherin expression levels are associated with CSS, PFS and RFS. The clinical utility of these markers is valuable for pTa and pT1 urinary bladder cancer and should be further verified with prospective multi-center trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors declare that they have no competing interests, and all authors confirm accuracy.

Figures

Figure 1.
Figure 1.
Representative microphotographs of E-cadherin (a), Ki-67 (b), and p53 (c) expression in urothelial bladder cancer (UBC). Positive and negative controls, respectively, for each biomarker: E-cadherin (d,g); Ki-67 (e,h); p53 (f,i). Scale bars: 100 μm.
Figure 2.
Figure 2.
Kaplan-Meier analysis of p53 NMIBC patients in relation to CSS. (Log-rank P-value = 0.936).
Figure 3.
Figure 3.
Kaplan-Meier analysis of Ki-67 NMIBC patients in relation to CSS. (Log-rank P-value <0.001).
Figure 4.
Figure 4.
Kaplan-Meier analysis of E-cadherin NMIBC patients in relation to CSS. (Log-rank P-value <0.001).
Figure 5.
Figure 5.
Kaplan-Meier analysis of Ki-67 NMIBC patients in relation to PFS. (Log-rank P-value <0.001).
See this image and copyright information in PMC

References

    1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-87. - PubMed
    1. Karaoglu I, van der Heijden AG, Witjes JA. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer. World J Urol 2014;32:651-9. - PubMed
    1. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, et al. EAU Guidelines on non–muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 2017;71:447-61. - PubMed
    1. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96-100. - PubMed
    1. Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000;24:980-7. - PubMed

MeSH terms

LinkOut - more resources